Table 3.
Measurements of inflammatory parameters at onset and conclusion of participation in placebo and carrageenan study groups
| Inflammatory | Group 1. | Group 1. | Group 2. | Group 2. |
| Parameter | Carrageenan-containing | Carrageenan-containing | Placebo capsules | Placebo capsules |
| Value±S.D. | capsules –onset | capsules –conclusion | –onset | –conclusion |
| IL-6 (pg/ml) | 2.57 (0.97) | 5.00 (2.31)a | 3.69 (1.68) | 3.06 (1.44) |
| Calprotectin (μg/gm) | 133 (125) | 171 (143)b | 149 (112) | 111 (91) |
| IL-8 (pg/ml) | 266 (307) | 207 (180) | 151 (65) | 169 (109) |
| TNF-α (pg/ml) | 3.8 (0.9) | 6.3 (4.9) | 21.0 (25.2) | 10.8 (10.4) |
| MCP-1 (pg/ml) | 161 (84) | 188 (157) | 55 (26) | 107 (46) |
| NF-κB (% normal | 214 (159) | 192 (97) | 165 (45) | 171 (66) |
| control WBC) | ||||
| BCL10 (ng/ml) | 2.02 (0.73) | 1.85 (0.36) | 1.83 (0.64) | 1.98 (0.61) |
a) for p = 0.02, paired t-test, two-tailed; n = 5, b) for p = 0.06, paired t-test, two-tailed; n = 5, BCL = B-cell leukemia/lymphoma; IL = Interleukin; MCP = monocyte chemoattractant protein; NF-κB = nuclear factor kappaB; S.D. = standard deviation; TNF = tumor necrosis factor.